IL5 and chronic rhinosinusitis with nasal polyps: With the European approval of mepolizumab as an add-on therapy with intranasal GCS for the treatment of adults with severe CRSwNP that cannot be adequately controlled with systemic GCS and/or surgery, an IL-5-addressing biologic has been available for the treatment of CRSwNP and can be prescribed and reimbursed in Germany since 2021 [74].